The role of costimulation in autoimmune demyelination

Journal of Neuroimmunology

Volumn 107, Issue 2, 2000, Pages 205-215

  Racke, Michael K ^a   Ratts, Robert B ^a   Arredondo, Lachelle ^a   Perrin, Peter J ^b   Lovett Racke, Amy ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoimmune demyelination; Costimulation; Experimental allergic encephalomyelitis; Immunologically based therapy; Multiple sclerosis

Indexed keywords

ANTIBODY; AUTOANTIGEN; CD28 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENCEPHALITOGENIC PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; L SELECTIN; LYMPHOKINE; LYMPHOTOXIN; MYELIN; PERTUSSIS TOXIN; T LYMPHOCYTE RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; CONFERENCE PAPER; DEMYELINATION; HUMAN; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; MULTIPLE SCLEROSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 0034710342     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00230-7     Document Type: Conference Paper

References (106)

1. Allegretta M., Nicklas J.A., Sriram S., Albertini R.J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 247:1990;718-721.
2. Anderson D.W., Ellenberg J.H., Leventhal C.M., Reingold S.C., Rodriguez M., Silberberg D.H. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 31:1992;333-336.
3. Ando D.G., Clayton J., Kono D., Urban J.L., Sercarz E.E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 124:1989;132-143.
4. Arnason B.G. Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol. Clin. 1:1983;765-782.
5. Azuma M., Yssel H., Phillips J.H., Spits H., Lanier L.L. Functional expression of B7/BB1 on activated T lymphocytes. J. Exp. Med. 177:1993;845-850.
6. Bachmaier, Pummerer C., Shahinian A., ionescu J., Neu N., Mak T.W., Penninger J.M. Induction of autoimmunity in the absence of CD28 costimulation. J. Immunol. 157:1996;1752-1757.
7. Boehme S.A., Lenardo M.J. Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. Eur. J. Immunol. 23:1993;1552-1560.
8. Bretscher P. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today. 13:1992;74-76.
9. Campbell B., Vogel P.J., Fisher E., Lorenz R. Myelin basic protein administration in multiple sclerosis. Arch. Neurol. 29:1973;10-15.
10. Cohen J.J. Apoptosis. Immunol. Today. 14:1993;126-130.
11. Correale J., Gilmore W., McMillan M., Li S., McCarthy K., Le T., Weiner L.P. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154:1995;2959-2968.
12. Critchfield J.M., Racke M.K., Zuniga-Pflucker J.C., Cannella B., Raine C.S., Goverman J., Lenardo M.J. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1994;1139-1143.
13. Croft M., Bradley L.M., Swain S.L. Naive versus memory CD4 T cell response to antigen: Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J. Immunol. 152:1994;2675-2685.
14. Cross A.H., Tuohy V.K., Raine C.S. Development of reactivity to new myelin antigens during chronic relapsing autoimmune demyelination. Cell. Immunol. 146:1993;261-269.
15. Cross A.H., Lyons J.A., San M., Keeling R.M., Ku G., Racke M.K. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing, and chronic experimental autoimmune encephalomyelitis. Eur. J. Immunol. 29:1999;1753-1761.
16. Damle N.K., Hansen J.A., Good R.A., Gupta S. Monoclonal antibody analysis of human T lymphocyte subpopulations exhibiting autologous mixed lymphocyte reaction. Proc. Natl. Acad. Sci. USA. 78:1981;5096-5098.
17. Damle N.K., Klussman K., Linsley P.S., Aruffo A. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. J. Immunol. 148:1992;1985-1992.
18. Freedman A.S., Freeman G.J., Rhynhart K., Nadler L.M. Selective induction of B7/BB-1 on interferon-g stimulated monocytes: A potential mechanism for amplification of T cell activation. Cell. Immunol. 137:1991;429-437.
19. Freeman G.J., Borriello F., Hodes R.J., Reiser H., Hathcock K.S., Laszlo G., McKnight A.J., Kim J., Du L., Lombard D.B., Gray G.S., Nadler L.M., Sharpe A.H. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science. 262:1993;907-909.
20. Freeman G.J., Gribben J.G., Boussiotis V.A., Ng J., Restivo V.A., Lombard L.A., Gray G.S., Nadler L.M. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science. 262:1993;909-911.
21. Freeman G.J., Borriello F., Hodes R.J., Reiser H., Gribben J.G., Ng J.W., Kim J., Goldberg J.M., Hathcock K., Laszlo G., Lombard L.A., Wang S., Gray G.S., Nadler L.M., Sharpe A.H. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:1993;2185-2192.
22. Fritz R.B., McFarlin D.E. Encephalitogenic epitopes of myelin basic protein. Sercarz E.E. Antigenic Determinants and Immune Response. 1989;101-125 Karger, Basel.
23. Fritz R.B., Zhao M.-L. Thymic expression of myelin basic protein (MBP): activation of MBP-specific T cells by thymic cells in the absence of exogenous MBP. J. Immunol. 157:1996;5249-5253.
24. Fritz R.B., Skeen M.J., Jen-Chou C.H., Garcia M., Egorov I.K. Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. J. Immunol. 134:1985;2328-2332.
25. Gaur A., Wiers B., Liu A., Rothbard J., Fathman G.C. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 258:1993;1491-1493.
26. Genain C.P., Abel K., Belmar N., Villinger F., Rosenberg D.P., Linington C., Raine C.S., Hauser S.L. Late complications of immune deviation therapy in a nonhuman primate. Science. 274:1996;2054-2057.
27. Gimmi C.D., Freeman G.J., Gribben J.G., Gray G., Nadler L.M. Human T cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA. 90:1993;6586-6590.
28. Gonsette R.E., Delmotte P., Demonty L. Failure of basic protein therapy for multiple sclerosis. J. Neurol. 216:1977;27-31.
29. Goverman J., Woods A., Larson L., Weiner L.P., Hood L., Zaller D.M. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell. 72:1993;551-560.
30. Green J.M., Noel P.J., Sperling A.I., Walunas T.L., Gray G.S., Bluestone J.A., Thompson C.B. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1:1994;501-508.
31. Green J.M., Noel P.J., Sperling A.I., Walunas T.L., Gray G.S., Bluestone J.A., Thompson C.B. Absence of B7-dependent responses in CD28-deficient mice. Immunity. 1:1994;501-508.
32. Greenfield E.A., Howard E., Paradis T., Nguyen K., Benazzo F., McLean P., Hšllsberg P., Davis G., Hafler D.A., Sharpe A.H., Freeman G.J., Kuchroo V.K. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA-4 binding: implications for induction of antitumor immunity to T cell tumors. J. Immunol. 158:1997;2025-2034.
33. Hathcock K.S., Laszlo G., Pucillo C., Linsley P., Hodes R.J. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:1994;631-640.
34. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1995;655-661.
35. Jacobs L.D., Cookfair D.L., Rudick R.A. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
36. Jenkins M.K., Johnson J.G. Molecules involved in T-cell costimulation. Curr. Opin. Immunol. 5:1993;351-367.
37. Johnson K.P., Brooks B.R., Cohen J.A. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 45:1995;1268-1276.
38. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol. Today. 15:1994;321-331.
39. Karpus W.J., Gould K.E., Swanborg R.H. CD4+ suppressor cells of autoimmune encephalomyelitis respond to T cell receptor-associated determinants on effector cells by interleukin-4 secretion. Eur. J. Immunol. 22:1992;1757-1763.
40. Kawabe Y., Ochi A. Programmed cell death and extrathymic reduction of Vb8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature. 349:1981;295-298.
41. Kennedy M.K., Tan L.-J., Dal Canto M.C., Tuohy V.K., Lu Z., Trotter J.L., Miller S.D. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J. Immunol. 144:1990;909-915.
42. Kennedy M.K., Torrance D.S., Picha K.S., Mohler K.M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
43. Kerr J.F.R., Harmon B.V. Definition and incidence of apoptosis: an historical perspective. Tomei D., Cope F. Apoptosis: The Molecular Basis of Cell Death. 1991;5-29 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
44. Khoruts A., Miller S.D., Jenkins M.K. Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J. Immunol. 155:1995;5011-5017.
45. King C.L., Stupi R.J., Craighead N., June C.H., Thyphronitis G. CD28 activation promotes Th2 subset differentiation by human CD4+ T cells. Eur. J. Immunol. 25:1995;587-595.
46. Kuchroo V.K., Das M.B., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
47. Larsen C.P., Ritchie S.C., Hendrix R., Linsley P.S., Hathcock K.S., Hodes R.J., Lowry R.P., Pearson T.C. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J. Immunol. 152:1994;5208-5219.
48. Lehmann P.V., Forsthuber T., Miller A., Sercarz E.E. Spreading of T cell autoimmunity to cryptic determinants of an autoantigen. Nature. 358:1992;155-157.
49. Lenardo M.J. Interleukin-2 programs mouse ab T lymphocytes for apoptosis. Nature. 353:1991;858-861.
50. Lenschow D.J., Zheng Y., Thistlethwaite J.R., Montag A., Brady W., Gibson M.G., Linsley P.S., Bluestone J.A. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science. 265:1992;1225-1227.
51. Lenschow D.J., Ho S.C., Sattar H., Rhee L., Gray G., Nabavi N., Herold K.C., Bluestone J.A. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the non-obese diabetic mouse. J. Exp. Med. 181:1995;1145-1155.
52. Lenschow D.J., Herold K.C., Rhee L., Patel B., Koons A., Qin H.Y., Fuchs E., Singh B., Thompson C.B., Bluestone J.A. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity. 5:1996;285-293.
53. Lin H., Bolling S.F., Linsley P.S., Wei R.Q., Gordon D., Thompson C.B., Turka L.A. Long-term acceptance of major histocompatibility mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178:1993;1801-1806.
54. Linington C., Bradl M., Lassman H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am. J. Pathol. 130:1988;443-454.
55. Linsley P.S., Greene J.L., Tan P., Bradshaw J., Ledbetter J.A., Anasetti C., Damle N.K. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J. Exp. Med. 176:1992;1595-1604.
56. Linsley P.S., Greene J.I., Brady W., Bajorath J., Ledbetter J.A., Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1:1994;793-801.
57. Liu Y., Janeway C.A. Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc. Natl. Acad. Sci. USA. 89:1992;3845-3849.
58. Lovett-Racke A.E., Martin R., McFarland H.F., Racke M.K., Utz U. Longitudinal study of myelin basic protein-specific T cell receptors during the course of multiple sclerosis. J. Neuroimmunol. 78:1997;162-171.
59. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: A marker of activated/memory T cells. J. Clin. Invest. 101:1998;725-730.
60. Martin R., McFarland H.F., McFarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
61. Martin R., Voskuhl R., Flerlage M., McFarlin D.E., McFarland H.F. Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann. Neurol. 34:1993;524-535.
62. Martyn C.N. The epidemiology of multiple sclerosis. Matthews W.B. McAlpine's Multiple Sclerosis. 2nd Edition :1991;Churchill Livingstone, New York, NY. Ch. 1.
63. McCarron R.M., Fallis R.J., McFarlin D.E. Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 29:1990;73-79.
64. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of EAE in the SJL/J Mouse. J. Exp. Med. 182:1995;75-85.
65. Miller S.D., Karpus W.J. The immunopathogenesis and regulation of T-cell mediated demyelinating diseases. Immunol. Today. 15:1994;356-361.
66. Miller S.D., Vanderlugt C.L., Lenschow D.J., Pope J.G., Karandikar N.J., Dal Canto M.C., Bluestone J.A. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity. 3:1995;739-745.
67. Moskophidis D., Lechner F., Pircher H., Zinkernagel R.M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 362:1993;758-761.
68. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173.
69. Murphy E.E., Terres G., Macatonia S.E., Hsieh C.S., Mattson J., Lanier L., Wysocka M., Trinchieri G., Murphy K., O'Garra A. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation. J. Exp. Med. 180:1994;223-231.
70. Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:1995;39-43.
71. Perez V.L., Parijs L.V., Biuckians A., Zheng X.X., Strom T.B., Abbas A.K. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:1997;411-417.
72. Pender M.P., McCombe P.A., Yoong G., Nguyen K.B. Apoptosis of ab T lymphocytes in the nervous system in experimental autoimmune encephalomyelitis: Its possible implications for recovery and acquired tolerance. J. Autoimmunity. 5:1992;401-410.
73. Perrin P.J., Scott D., June C.H., Racke M.K. B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis. Immunol. Res. 14:1995;189-199.
74. Perrin P.J., Scott D., Quigley L., Albert P.S., Feder O., Gray G.S., Abe R., June C.H., Racke M.K. The role of B7:CD28/CTLA4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 154:1995;1481-1490.
75. Perrin P.J., Scott D., Davis T.A., Gray G.S., Doggett M.J., Abe R., June C.H., Racke M.K. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. J. Neuroimmunol. 65:1996;31-39.
76. Perrin P.J., Maldonado J.H., Davis T.A., June C.H., Racke M.K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 157:1996;1333-1336.
77. Perrin P.J., June C.H., Maldonaldo J.H., Ratts R., Racke M.K. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 163:1999;1704-1710.
78. Perrin P.J., Lavi E., Zekavat S.A., Rumbley C.A., Phillips S.M. Experimental autoimmune meningitis: a novel neurological disease in CD28-deficient mice demonstrate the importance of CD28 in T cell differentiation. Clin. Immunol. 91:1999;41-49.
79. Pette M., Fujita K., Kitze B., Whitaker J.N., Albert E., Kappos L., Wekerle H. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology. 40:1990;1770-1776.
80. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A.D., Raine C.S., Shevach E.M., Röcken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1994;1961-1966.
81. Racke M.K., Scott D.E., Quigley L., Gray G.S., Abe R., June C.H., Perrin P.J. Distinct roles for B7-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 96:1995;2195-2203.
82. Racke M.K., Critchfield J.M., Quigley L., Cannella B., Raine C.S., McFarland H.F., Lenardo M.J. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann. Neurol. 39:1996;46-56.
83. Raine C.S. Biology of disease. Analysis of autoimmune demyelination: its impact upon multiple sclerosis. Lab. Invest. 50:1984;608-635.
84. Raine C.S., Traugott U., Stone S.H. Suppression of chronic allergic encephalomyelitis: relevance to multiple sclerosis. Science. 201:1978;445-448.
85. Ratts, R.R., Arredondo, L.R., Bittner, P., Perrin, P.J., Lovett-Racke, A.E., Racke M.K., 1999a. The role of CTLA-4 in tolerance induction and T cell differentiation in experimental autoimmune encephalomyelitis: Intravenous antigen administration. Int. Immunol. (in press).
86. Ratts, R.R., Arredondo, L.R., Bittner, P., Perrin, P.J., Lovett-Racke, A.E., Racke, M.K., 1999b. The role of CTLA-4 in tolerance induction and T cell differentiation in experimental autoimmune encephalomyelitis: Intraperitoneal antigen administration. Int. Immunol. (in press).
87. Röcken M., Racke M., Shevach E.M. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunol. Today. 17:1996;225-231.
88. Russell J.H., White C.L., Loh D.Y., Meleedy-Rey P. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc. Natl. Acad. Sci. USA. 88:1991;2151-2155.
89. Sadovnick A.D., Ebers G.C. Epidemiology of multiple sclerosis: a critical overview. Can. J. Neurol. Sci. 20:1993;17-29.
90. Sagerstrom C.G., Kerr E.M., Allison J.P., Davis M.M. Activation and differentiation requirements of primary T cells in vitro. Proc. Natl. Acad. Sci. USA. 90:1993;8987-8991.
91. Sansom D.M., Hall N.D. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur. J. Immunol. 23:1993;295-298.
92. Schlüsener H., Wekerle H. Autoaggressive T lymphocyte lines recognize the encephalitogenic region of myelin basic protein; in vitro selection from unprimed T cell populations. J. Immunol. 135:1985;3128-3133.
93. Schmied M., Breitschopf H., Gold R., Zischler H., Rothe G., Wekerle H., Lassmann H. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143:1993;446-452.
94. Scholz C., Patton K.T., Anderson D.E., Freeman G.J., Hafler D.A. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 160:1998;1532-1538.
95. Schumacher G.A. Critique of experimental trials of therapy in multiple sclerosis. Neurology. 24:1974;1010-1014.
96. Schweitzer A.N., Borriello F., Wong R.C.K., Abbas A.K., Sharpe A.H. Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J. Immunol. 158:1997;2713-2722.
97. Su X.-M., Sriram S. Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein. J. Neuroimmunol. 34:1991;181-190.
98. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing critical negative regulatory role of CTLA-4. Immunity. 3:1995;541-547.
99. Trotter J.L., Damico C.A., Cross A.H., Pelfrey C.M., Karr R.W., Fu X.-T., McFarland H.F. HPRT mutant T-cell lines from multiple sclerosis patients recognize myelin proteolipid protein peptides. J. Neuroimmunol. 75:1997;95-103.
100. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 170:1995;985-988.
101. Webb C., Morris C., Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 63:1990;1249-1256.
102. Windhagen A., Newcombe J., Dangond F., Strand C., Woodroofe M.N., Cuzner M.L., Hafler D.A. Expression of costimulatory molecules B7-1 (CD-80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 182:1995;1985-1996.
103. Wucherpfennig K.W., Strominger J.L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80:1995;695-705.
104. Zamvil S.S., Steinman L. The lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8:1990;579-621.
105. Zeine R., Owens T. Loss rather than down regulation of CD4+ T cells as a mechanism for remission from experimental allergic encephalomyelitis. J. Neuroimmunol. 44:1993;193-198.
106. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:1994;973-984.